NCT01355003
GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) Post Marketing Surveillance Protocol
Merck Sharp & Dohme LLC·ClinicalTrials.govTerminated
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Papillomavirus Infections
- Study type
- Observational
Sponsor & location
- Primary sponsor
- Merck Sharp & Dohme LLC
Timeline & enrollment
- Phase
- N/A
- Start date
- Feb 01, 2008
- End date
- Jun 01, 2010
- Enrollment
- 1080 participants
Primary outcome
Number of participants with adverse events following any dose of vaccine
Summary
This study will collect safety information on the use of GARDASIL™ in the Philippines.
ICD-10 classifications
Papillomavirus as the cause of diseases classified to other chaptersPapovavirus infection, unspecified sitePapilloedema, unspecifiedViral infection, unspecifiedParvovirus as the cause of diseases classified to other chapters
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT01355003
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT01355003 through Pure Global AI's free database. This phase not specified trial is sponsored by Merck Sharp & Dohme LLC and is currently Terminated. The study focuses on Papillomavirus Infections. Target enrollment is 1080 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.